Document is current
Any future updates will be listed below
-
Authors
Broadbent, Eliza
Künzel, Sandrine H.
Pfau, Maximilian
Schmitz-Valckenberg, Steffen https://orcid.org/0000-0003-3358-9942
Fleckenstein, Monika
- License Information
-
More Information
Article History
Received: 1 May 2024
Revised: 10 September 2024
Accepted: 22 October 2024
First Online: 29 October 2024
Competing interests
: E. B.: none. S. K.: Novartis Pharma, Basel, (R), Chiesi GmbH, Hamburg, Germany (R). M. P.: Roch (R), Novartis (R), Boehringer IngelheimBoehringer Ingelheim (C), CenterVue (C,F). S. S.-V.:. AlphaRET (C), Apellis (C, R), Bayer (F), Fomycon (C), Carl Zeiss MediTec (F), eyeDNA Therapeutics (C), Galimedix (C), Heidelberg Engineering (F, R), Katairo (C), Kubota Vision (C), Novartis (C, F), Perceive Therapeutics (C), Pixium (C), Roche (C, F), SparingVision (C). M. F.: none.
